Anthony Kim, MD
Family Medicine · Fort Worth, TXNPI 1356311823
Payments from drug & device makers
Across 159 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$691
- Astellas Pharma US Inc$261
- AbbVie$185
- Nevro Corp.$175
- Novo Nordisk$146
- Johnson & Johnson$131
- plus $797 from 23 others
What the payments were for
- Food & beverage$2,34198%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 69 | $691 |
| Astellas Pharma US Inc | 15 | $261 |
| AbbVie(2 entities) | 10 | $185 |
| Nevro Corp. | 1 | $175 |
| Novo Nordisk | 11 | $146 |
| Johnson & Johnson(2 entities) | 7 | $131 |
| Lilly USA, LLC | 3 | $83 |
| Inspire Medical Systems, Inc. | 2 | $76 |
| Ardelyx, Inc. | 3 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $72 |
| Dexcom, Inc. | 4 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Boehringer Ingelheim | 3 | $42 |
| Pfizer | 3 | $40 |
| Merck | 3 | $39 |
| Sunovion Pharmaceuticals Inc. | 3 | $33 |
| Pylant Medical | 1 | $30 |
| Scilex Pharmaceuticals Inc. | 2 | $26 |
| Abbott | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Cranial Technologies, Inc | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Cipher Pharmaceuticals US LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnia$175
How this compares
$2,386 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 179 | $207,190 |
| RybelsusSemaglutide | 112 | $165,758 |
| OzempicSemaglutide | 121 | $145,675 |
| EliquisApixaban | 115 | $113,161 |
| FarxigaDapagliflozin Propanediol | 46 | $52,108 |
| JanuviaSitagliptin Phosphate | 40 | $44,346 |
| XareltoRivaroxaban | 31 | $42,221 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $40,251 |
| MounjaroTirzepatide | 23 | $30,664 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $20,160 |
| LinzessLinaclotide | 23 | $16,592 |
| MyrbetriqMirabegron | 22 | $16,377 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 102 | $12,540 |
| Gabapentin | 516 | $10,571 |
| CreonLipase/Protease/Amylase | 14 | $10,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $146 | $311,434233 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $42 | $216,968192 claims |
| PfizerEliquis | $40 | $113,161115 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $691 | $65,70093 claims |
| MerckJanuvia | $39 | $44,34640 claims |
| Johnson & JohnsonXarelto | $131 | $42,22131 claims |
| Lilly USA, LLCMounjaro | $83 | $30,66423 claims |
| AbbVieLinzess, Creon, Synthroid | $185 | $29,69589 claims |
| Astellas Pharma US IncMyrbetriq | $261 | $16,37722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Fort Worth
- William SegerFort Worth$27.5M
- Mark KochFort Worth$7.6M
- Isaac WatembergFort Worth$3.2M
- James HarveyFort Worth$2.7M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.